Seven years after the approval of the first immune checkpoint inhibitor for the treatment of metastatic melanoma, immunotherapy remains one of the primary areas of focus for oncology drug development. While checkpoint inhibition, chimeric antigen receptor T-cell therapy, and other immune-related therapies hold great promise in terms of both improved treatment outcomes and reduced side-effect ...

Ironically, the 2018 NASH-TAG conference in the Rocky Mountains featured much less snow than we have “enjoyed” in the northeast this winter. Weather forced one speaker to present remotely from his home—thank goodness web conferencing technology can now mitigate travel cancellations! In 2018, various speakers presented some very promising results including compounds from Gilead (GS-0976), Bristol ...

According to the WHO, obesity is an epidemic that kills at least 2.8 million people each year.  The number of obese children and adolescents worldwide has risen tenfold in the past four decades. Obesity is a major risk factor for heart disease, stroke, osteoarthritis, diabetes, liver disease such as non-alcoholic steatohepatitis (NASH), and certain cancers. Muscular dystrophies, such as Duchenne, ...

Clinical researchers have a zeal for excellence and an innate sense of purpose. We care deeply about healthcare and we want to see lives bettered and saved. Yet in spite of this noble drive, the daily rigor of standard procedures, meeting deadlines, and performing our fair share of tedious tasks can sometimes slow down our professional metabolism. Because we are an ethical and devoted type, we ...